Original ArtcileJournal of Young PharmacistsVol. 7 | Issue 2 | 2014 | pp. 106–112Open access
Impact of Severity of the Disease on Cost of Illness and Quality of Life of Patients with Chronic Obstructive Pulmonary Disease
- 1,
- 1*,
- 2,
- 2,
- 2
- 1 Department of Pharmacy Practice, Faculty of Pharmacy, Sri Ramachandra Medical College and Research Institute Sri Ramachandra University, Chennai, INDIA.
- 2 Department of Chest and TB, Sri Ramachandra Medical College and Research Institute Sri Ramachandra University, Chennai, INDIA.
Published in Journal of Young Pharmacists
Correspondence: Vanitha Rani Nagasubramanian
Department of Pharmacy Practice, Faculty of Pharmacy, Sri Ramachandra Medical College and Research Institute Sri Ramachandra University, Chennai, INDIA.
Email: vanithak9@rediffmail.com
Copyright: © 2014 Manuscript Technomedia. This is an open access article.
- Published:
- Dec 31, 2014
- DOI:
- 10.5530/jyp.2015.2.8
How to cite
Kallaru, H., Nagasubramanian, V. R., Balakrishnan, H. P., Gopal, K., & Palani, T. (2014). Impact of Severity of the Disease on Cost of Illness and Quality of Life of Patients with Chronic Obstructive Pulmonary Disease. Journal of Young Pharmacists, 7(2), 106–112. https://doi.org/10.5530/jyp.2015.2.8
Abstract
Objective: The objective of the study was to assess the cost of illness of COPD and the influence of severity of the disease over cost of illness and the quality of life. Materials and Methods: The study was conducted in 105 patients aged > 40 years and <70 years, diagnosed with stages II, III and IV COPD. Cost of illness (direct and indirect costs) was calculated in Indian rupees from the expenditures of the hospital visits, pharmacotherapy, oxygen therapy, biochemical investigations, diagnostic procedures, physiotherapy and hospitalization due to acute exacerbations by patient interview and review of patient’s case history, medical and billing records. Quality of life of 50 patients in Stage III and Stage IV COPD was estimated using St. George’s Respiratory Questionnaire (SGRQ) score. Results: The mean cost spent by the patients with stage II COPD was Rs.3179.62 ± 99.01 per visit to the hospital, stage III was Rs.16414.79 ± 8365.79 and stage IV was Rs.44077.16 ± 15686.21 per visit. As the severity of COPD increased both direct and indirect costs increased and the quality of life of the patient decreased significantly (P=0.000). Out of the total costs, highest was spent on direct medical costs (81.2%). Direct nonmedical costs contributed to 10.6% and indirect costs to 8%. The drivers of the total cost were found to be hospitalizations (36.2%) and length of stay. Conclusion: Since acute exacerbations are the main cause of hospitalization among COPD patients, strategies to prevent severe exacerbations could be very cost effective and may improve the quality of life.
Keywords
Subject
Article metadata
| Title | Impact of Severity of the Disease on Cost of Illness and Quality of Life of Patients with Chronic Obstructive Pulmonary Disease |
|---|---|
| Authors | Hindu Kallaru; Vanitha Rani Nagasubramanian; Hari Prasad Balakrishnan; Kannan Gopal; Thennarasu Palani |
| Affiliations | Department of Pharmacy Practice, Faculty of Pharmacy, Sri Ramachandra Medical College and Research Institute Sri Ramachandra University, Chennai, INDIA.; Department of Chest and TB, Sri Ramachandra Medical College and Research Institute Sri Ramachandra University, Chennai, INDIA. |
| Corresponding author | vanithak9@rediffmail.com |
| Journal | Journal of Young Pharmacists |
| Volume / Issue | Vol. 7, Issue 2 (2014) |
Also in this issue
- Environmental Safety – Breath for Next Generationpp. 61–62
- Studies on Anti microbial Potential of Non-antibiotics on Resistant Bacteria – A Reviewpp. 63–68
- Drug Safety Surveillance: Modern Trends and Industrial Actionpp. 69–75
- ABC and VED Analysis of the Pharmacy Store of a Tertiary Care, Academic Institute of the Northern India to Identify the Categories of Drugs Needing Strict Management Controlpp. 76–80
- Development and Validation of Stability Indicating RP-HPLC Method for Simultaneous Estimation of Paracetamol and Flupirtine maleate in Pure and Pharmaceutical Dosage Formspp. 81–88
Readers Also Viewed
Development and Validation of UV/visible Spectrophotometric Method for Estimation of Piroxicam from Bulk and Formulation
Sandip Mohan Honmane, Kunal Rajaram Yadav, Yuvraj Dilip Dange
Apr 23, 2025
Effects of Artificial Intelligence on Academic Performance of Library and Information Science University Students: A Meta-Analysis (2023-2025)
Kayode Sunday John Dada
Aug 6, 2026
Bridging Innovation and Impact: A Multidisciplinary Approach to Contemporary Research Challenges
Mueen Ahmed KK
Aug 11, 2026